预约演示
更新于：2025-01-17
Droperidol
氟哌利多
更新于：2025-01-17
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1970-06-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H22FN3O2 |
InChIKeyRMEDXOLNCUSCGS-UHFFFAOYSA-N |
CAS号548-73-2 |
关联
35
项与 氟哌利多 相关的临床试验NCT06726811
Low-Dose Droperidol and Its Association with QTc Interval Changes in Emergency Department Patients
IRCT20230128057257N1
Comparison of the effects of ginger, ondansetron and droperidol on nausea and vomiting after hysterectomy
NCT05401058
Low-dose Droperidol for Prevention of Postoperative Delirium in Elderly Patients After Non-cardiac Surgery: A Randomized, Double-blind, Placebo-controlled Trial
100 项与 氟哌利多 相关的临床结果
登录后查看更多信息
100 项与 氟哌利多 相关的转化医学
登录后查看更多信息
100 项与 氟哌利多 相关的专利（医药）
登录后查看更多信息
2,458
项与 氟哌利多 相关的文献（医药）2025-04-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
DRopEridol for Abdominal pain in the emergency department for Morphine Equivalent Reduction. The DREAMER study
Article
作者: Malka, Sarah T ; Gilbert, Brian W ; Di Paola, Sean G ; Townsend, Brock R ; Nisly, Andrea E
INTRODUCTION:
Droperidol is a dopamine-2 receptor antagonist in the class of butyrophenone antipsychotics with antiemetic, sedative, analgesic, and anxiolytic properties. In the postoperative setting, droperidol provides an opioid sparing effect and decreases nausea/vomiting. Another butyrophenone antipsychotic, haloperidol, has been shown to reduce morphine milliequivalents (MME) administered when used for abdominal pain in the emergency department (ED). The purpose of this study is to evaluate if the use of droperidol for undifferentiated abdominal pain reduces the amount of MME administered in the ED.
METHODS:
This retrospective, single-center study included patients ≥18 years old who presented to the ED for undifferentiated abdominal pain. Patients must have had two separate encounters for abdominal pain, one encounter where they received droperidol and one encounter where they did not receive droperidol but did receive an opioid. The primary outcome was the difference in MME administered between the two separate patient encounters. Secondary outcomes included utilization rates of rescue antiemetics, rescue analgesics, admission to the hospital, hospital length of stay, and adverse effects (including arrhythmias and extrapyramidal symptoms).
RESULTS:
Fifty patients with self-matched encounters were evaluated. A majority of the patients were female (33/50, 66 %) with a median age of 38 years old. All doses of droperidol were intravenous and the majority of patients received a dose of 2.5 mg (34/50, 68 %; range 1.25-5 mg). Non-droperidol encounters received significantly more MME compared to droperidol encounters (19.4 MME [IQR 12-30] vs 10 MME [IQR 0-20], p-value 0.0002). There were no statistically significant differences between the secondary outcomes.
CONCLUSION:
Among patients presenting to the ED for abdominal pain, droperidol administration resulted in a significant reduction in MME administration. Future research should include prospective studies, comparison of droperidol to haloperidol, and investigate droperidol use beyond the ED for these encounters.
2025-02-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Agitation: Neurobiology and current management guidelines
Review
作者: Van Remmen, Sarah ; Mahmood, Sara ; Rullo, Mario ; Miller, Christopher W T
There have been important updates in the guidelines for the management of agitation in emergency room settings, including psychiatric emergency services. This manuscript provides a synthesis of current recommendations, combined with a detailed breakdown of the neurobiology of agitation, linking these neuroscientific dimensions with the pharmacological profiles of the drugs recommended by practice guidelines (as well as the profiles of other important agents). Since Project BETA (Best Practices in Evaluation and Treatment of Agitation) guidelines were published in 2012 (by the American Association for Emergency Psychiatry), there have been several developments in the standard of care, including an increase in use of ketamine and droperidol. Recommended treatment strategies for clinicians will be presented, including consideration of how to address specific causes of agitation.
2025-01-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Comparing the cardiorespiratory safety of parenteral olanzapine and benzodiazepines to parenteral haloperidol/droperidol and benzodiazepines in emergency department patients
Article
作者: Miller, Christopher D ; Meola, Gregory ; Miller, Christopher D. ; Darko, William ; Bradley, Katherine ; Feldman, Elizabeth A. ; Seabury, Robert ; Feldman, Elizabeth A ; Schrader, Joshua
INTRODUCTION:
This study sought to assess the cardiorespiratory safety of parenteral olanzapine and benzodiazepine combination treatment compared to parenteral droperidol or haloperidol and benzodiazepine combination treatment.
MATERIALS AND METHODS:
This was a retrospective chart review conducted in adult emergency department patients who received intramuscular (IM) or intravenous (IV) droperidol, haloperidol, or olanzapine within one hour of IM or IV benzodiazepine. Patients were stratified into groups based on whether they received either olanzapine in combination with a benzodiazepine (n = 48) or droperidol or haloperidol in combination with a benzodiazepine (n = 48).
RESULTS:
Patients in each group had a decrease in their systolic blood pressure (SBP) after IM/IV olanzapine and IM/IV droperidol or haloperidol when used in combination with an IM/IV benzodiazepine ((Olanzapine + benzodiazepine (mmHg), median (IQR): Pre-SBP: 132 (117-151) vs. Post-SBP: 117 (99-131), p < 0.01) (Droperidol or haloperidol + benzodiazepine (mmHg), median (IQR): Pre-SBP: 138 (122-149) vs. Post-SBP: 106 (98-127), p < 0.01)). Both groups had similar percent SBP decreases post-combination treatment (Olanzapine + benzodiazepine (15.6 %) vs. Droperidol or haloperidol + benzodiazepine (15.2 %); p = 0.55). We did not observe any statistically significant between group differences for hypotension (Olanzapine + benzodiazepine: 1/48, 2.1 % vs. Droperidol or haloperidol + benzodiazepine: 3/48, 6.3 %; p = 0.62)), escalation in oxygen requirements (Olanzapine + benzodiazepine: 7/48, 14.6 %) vs. Droperidol or haloperidol + benzodiazepine: 5/48, 10.4 %; p = 0.76)), or intubation due to cardiorespiratory depression (Olanzapine + benzodiazepine: 0/0, 0 % vs. Droperidol or haloperidol + benzodiazepine: 0/0, 0 %; p = 1.00)).
CONCLUSION:
This study found decreases in SBP after administering parenteral olanzapine and parenteral droperidol or haloperidol in combination with a parenteral benzodiazepine. The percent change in SBP and the frequency of hypotensive episodes post-combination treatment were not different between groups. There were also no differences between groups in need of increased oxygen requirements post-combination treatment or need for intubation due to cardiorespiratory depression. This study suggests parenteral olanzapine in combination with a parenteral benzodiazepine may have comparable cardiorespiratory safety versus parenteral droperidol or haloperidol in combination with a parenteral benzodiazepine when treating agitation in the adult ED.
100 项与 氟哌利多 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 妊娠剧吐 | 中国 | 1989-01-01 | |
| 麻醉 | 日本 | 1971-05-10 | |
| 恶心和呕吐 | 美国 | 1970-06-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 322 | DEX, OND, and placebo | 構齋願獵鑰構襯鹹糧醖(膚壓廠襯餘齋鏇齋膚夢) = 製簾鏇衊夢鑰觸醖獵鑰 願窪膚鑰夢範醖觸範繭 (簾鏇鑰構廠鑰餘窪膚簾 ) | - | 2017-06-01 | ||
DEX, OND, and DRO | 構齋願獵鑰構襯鹹糧醖(膚壓廠襯餘齋鏇齋膚夢) = 餘襯壓遞構觸夢鹽淵製 願窪膚鑰夢範醖觸範繭 (簾鏇鑰構廠鑰餘窪膚簾 ) | ||||||
N/A | - | 選醖襯糧鬱衊簾網築淵(淵齋獵鹽鹽醖憲製壓構) = 鏇夢憲簾鹹蓋壓窪製顧 構壓範餘鏇襯築製鹹願 (蓋顧製鏇願網鹽範淵鬱 ) | - | 1991-01-01 | |||
Droperidol + placebo pretreatment | 築顧選簾簾餘襯繭觸膚(築齋衊繭憲齋獵憲壓廠) = 繭壓製醖淵觸鏇糧鬱膚 齋簾齋艱顧簾積蓋網艱 (襯衊蓋鑰獵選鹽膚繭選 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用